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Background: We aimed to evaluate the multivariate association between functional microvascular variables and
clinical-laboratorial-anthropometrical measurements.
Methods: Data from 189 female subjects (34.0±15.5 years, 30.5±7.1 kg/m2), who were non-smokers, non-regular
drug users, without a history of diabetes and/or hypertension, were analyzed by principal component analysis
(PCA). PCA is a classical multivariate exploratory tool because it highlights common variation between variables
allowing inferences about possible biological meaning of associations between them, without pre-establishing
cause-effect relationships. In total, 15 variables were used for PCA: body mass index (BMI), waist circumference,
systolic and diastolic blood pressure (BP), fasting plasma glucose, levels of total cholesterol, high-density lipoprotein
cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), insulin, C-reactive protein (CRP),
and functional microvascular variables measured by nailfold videocapillaroscopy. Nailfold videocapillaroscopy was
used for direct visualization of nutritive capillaries, assessing functional capillary density, red blood cell velocity
(RBCV) at rest and peak after 1 min of arterial occlusion (RBCVmax), and the time taken to reach RBCVmax (TRBCVmax).
Results: A total of 35% of subjects had metabolic syndrome, 77% were overweight/obese, and 9.5% had impaired
fasting glucose. PCA was able to recognize that functional microvascular variables and
clinical-laboratorial-anthropometrical measurements had a similar variation. The first five principal components
explained most of the intrinsic variation of the data. For example, principal component 1 was associated with BMI,
waist circumference, systolic BP, diastolic BP, insulin, TG, CRP, and TRBCVmax varying in the same way. Principal
component 1 also showed a strong association among HDL-c, RBCV, and RBCVmax, but in the opposite way.
Principal component 3 was associated only with microvascular variables in the same way (functional capillary
density, RBCV and RBCVmax). Fasting plasma glucose appeared to be related to principal component 4 and did not
show any association with microvascular reactivity.
Conclusions: In non-diabetic female subjects, a multivariate scenario of associations between classic clinical
variables strictly related to obesity and metabolic syndrome suggests a significant relationship between these
diseases and microvascular reactivity.
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The microcirculation, represented by arterioles, capillar-
ies and venules, is where blood/tissue nutrition and ex-
change effectively takes place. Several techniques have
been proposed and used to assess microvascular reactiv-
ity in the microcirculation. Among these techniques,
nailfold videocapillaroscopy is a non-invasive technique
that actually visualizes capillaries, assessing skin nutritive
microvascular flow and reactivity.
The relationship between blood glucose and the micro-
circulation requires further clarification, because even in
non-diabetics, insulin resistance is a significant predictor
of poor outcome in patients admitted with myocardial in-
farction [1,2]. Additionally, many studies of small sample
sizes have documented that skin capillary recruitment, an
index of healthy tissue status, is related to insulin resist-
ance and blood pressure (BP), even in normotensive [3]
and obese subjects [4,5]. Microvascular dysfunction has
also been observed in non-diabetic metabolic syndrome
patients [6] and in non-diabetic obese women independ-
ently of metabolic syndrome diagnosis [7]. The concept of
microvascular dysfunction as the pathophysiological basis
of a pre-receptor defect aggravating insulin resistance and
its cause-effect relationship is still a matter of debate [8].
The endothelial glycocalyx is a network of membrane-
bound proteoglycans and glycoproteins covering the
endothelium in the luminal side. Both endothelium and
plasma-derived soluble molecules integrate into this
mesh. In healthy vessels glycocalyx determines vascular
permeability, attenuates blood cell–vessel wall interac-
tions, mediates shear stress sensing, enables balanced
signaling, and fulfills a vasculoprotective role. However,
in states of disease, experimental settings [9,10] have
suggested that the altered glycocalyx homeostasis affects
endothelial function. Endothelial dysfunction is consid-
ered a precocious marker of atherosclerotic risk [11,12].
Moreover, because of the systemic nature of such dys-
function, which can simultaneously affect the coronary
circulation as well as peripheral vascular beds, it has
emerged that endothelial dysfunction in peripheral con-
duit arteries, small resistance vessels, and skin nutritive
microcirculation can be used as a surrogate marker of
coronary endothelial/microvascular damage [13,14].
Microvascular reactivity occurs at the level of small pre-
capillary arterioles, which are considered as the main reg-
ulators of capillary reactivity, also contributing to total
peripheral vascular resistance. Nailfold videocapillaro-
scopy is used to measure capillary variables that reflect
endothelial control at pre-capillary sites. In metabolic dis-
eases, correlations between findings with dynamic video-
capillaroscopy and observed findings in target organs still
need further elucidation. We have previously shown, that
in response to an insulin-sensitizing agent given to meta-
bolic syndrome normoglycemic patients, there was aconcomitant improvement in skin microvascular dysfunc-
tion [15] and in endothelial microvascular reactivity in
the muscle [16]. Notably, the drug that we used did not
affect endothelial-independent vasodilation, suggesting an
endothelial-dependent mechanism controlling capillary
parameters, as observed by nailfold videocapillaroscopy.
At microvascular sites during a reactive hyperemia re-
sponse, the role of reactive oxygen species secondary to
hypoxia could also influence microvascular reactivity.
The current study investigated a large number of
patients, tested by dynamic nailfold videocapillaroscopy,
in a sample of predominantly non-diabetic non-hyperten-
sive obese female subjects, analyzed by principal compo-
nent analysis. PCA is a multivariate exploratory approach
used to identify common variation between analyzed vari-
ables, aiming to reduce the dimensionality of the data set
and to detect the main source of inherent variation among
investigated variables. It should be noted that the main as-
sumption for this statistical method does not pre-establish
any possible cause-effect relationship between variables.
By grouping variables that behave in a similar fashion,
they form a principal component, and by doing so, the re-
searcher can suggest a biological phenomenon associated
with it, and even name the principal component. Our
study aimed to explore trends and associations between
microvascular function and classic clinical measurements
frequently used in a clinical cardiometabolic setting with-
out pre-establishing cause-effect phenomena.
Methods
Study population
The present study included data from research protocols
of the Clinical and Experimental Research Laboratory on
Vascular Biology (BioVasc), from November 2005 to May
2010, located in Rio de Janeiro, RJ, Brazil. All selected pro-
tocols were composed of only female subjects, because of
the small number of male subjects in our database. Inclu-
sion criteria were female subjects, non-regular drinkers,
and nonsmokers. To avoid drug bias on microvascular
function, no subject who was regularly using any drug, in-
cluding oral contraceptives and aspirin, and anti-hyperlip-
idemic, anti-hypertensive, or anti-hyperglycemic agents,
had their data entered in the database. Female adolescents
were included only at Tanner stage ≥ 4 [17]. Exclusion cri-
teria were pregnancy, prepubertal status, known history of
type 2 diabetes and/or hypertension, a history of previous
myocardial infarction or angina pectoris, hypertriglyceri-
demia (≥4.52 mmol/l), and systemic diseases, such as
autoimmune diseases (rheumatologic or thyroid diseases),
cancer, or active infection. In total, data from 189 subjects
(34.0±15.5 years, 30.5±7.1 kg/m2) were selected from a
large age range group, 12–64 years, and classified accord-
ing to body mass index (BMI) as normal weight, over-
weight, or obese [18,19]. They were also categorized as
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the International Diabetes Federation [20] or to the Joint
Interim Statement [21], respectively, for those up to 16
years or older than 16 years. Hypertension was categorized
according to The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) [22].
Study protocols were approved by the Ethical Commit-
tees of the Hospital da Lagoa (02/2005) and State Uni-
versity of Rio de Janeiro (COEP1950/2007). Written
informed consent was obtained for all subjects, while for
subjects <18 years old, a parent or guardian gave the
consent and signed it.
Data collection
Anthropometric, blood pressure, and laboratory
measurements
Anthropometric, blood pressure (BP), and laboratory mea-
surements were well-validated as previously reported
[4,6,7,15,23]. The body weight of subjects wearing light
clothing without shoes was measured with a 0.1-kg preci-
sion, height was measured to the nearest 0.5 cm, and BMI
was calculated as the weight in kilograms divided by the
square of height in meters. Waist circumference was
defined as the average of two measurements taken after
inspiration and expiration at the midpoint between the
lowest rib and the iliac crest. BP measurements were
made twice using the appropriate cuff size after the sub-
ject had rested for 5 min in the sitting position using a
standard sphygmomanometer. All laboratory measure-
ments were performed in duplicate after 10–12 h of fast-
ing using an automated method (Modular Analytics E
170 and P, Roche, Basel, Switzerland). Fasting plasma glu-
cose, total cholesterol, triglycerides (TG), and high-density
lipoprotein cholesterol (HDL-c) levels were measured
by the enzyme-colorimetric oxidase-peroxidase method
(inter-assay coefficient of variation [IECV]=1.09%), the en-
zymatic oxidase-peroxidase method (IECV=2.93%), the
enzymatic oxidase-peroxidase method (IECV=1.29%), and
the enzyme-colorimetric method without pre-treatment
(IECV=3.23%), respectively. Plasma low-density lipopro-
tein cholesterol (LDL-c) levels were calculated according
to the Friedewald equation. C-reactive protein (CRP)
levels were measured by immunoturbidimetry (IECV=8%).
Serum insulin levels were analyzed by eletrochemilumi-
nescence (IECV=10.6%). Subjects with fasting plasma glu-
cose levels ≥ 5.6 mmol/l were subsequently given an oral
glucose tolerance test according to the American Diabetes
Association criteria [24].
Microvascular assessment
Nailfold videocapillaroscopy was carried out and ana-
lyzed according to a standardized, well-validated meth-
odology, as previously described [4,6,7,25], for the 4thfinger of the left hand after a 10–12-h fast. All women
were acclimatized for 30 min in a room kept at 24 ± 1°C
before conducting the examination. Whether the men-
strual cycle phase affects microvascular reactivity is still
controversial [26,27], but we assessed skin microcircula-
tion without adjustment for the menstrual cycle because
it has previously been shown that the skin microcircula-
tion is not affected by menstrual phases [27]. Measure-
ments of microvascular reactivity were made by a Leica
DMLM microscope (Wetzlar, Germany), which was
equipped with an epiillumination system (100 W Xenon
lamp). Images were captured by a CCD video camera
(Samsung, Seoul, South Korea) coupled to the micro-
scope, visualized by a Kodo KBM1700E monitor (Seoul,
South Korea) and recorded by a super VHS videotape
recorder (Super VHSET, JVC, Malaysia). The subject’s
fingertip was fixed to the acrylic base by a metal loop to
minimize movement. The skin temperature of the finger
was monitored throughout the examination with an YSI
Precision 4000A digital thermometer (Dayton, OH, U.S.
A.) with the thermistor probe taped within 1 cm prox-
imal of the nailfold. A pressure cuff (1 cm wide) was
placed around the proximal phalanx of the 4th finger
and connected to a mercury manometer. The exam was
continuously recorded for later measurements of micro-
vascular variables using CapImage software [28] by the
same observer, who was not aware of any patient data.
With the patient at rest, functional capillary density,
which is the number of capillaries/unit tissue area
(mm2) with flowing red blood cells, was evaluated using
x250 magnification and an area of 3 mm of the distal
row of capillaries into three different areas (intra-assay
coefficient of variation [CV] = 5.5±2.5%). Red blood cell
velocity (RBCV) at rest and its peak after 1 min of arter-
ial occlusion (RBCVmax), which was achieved by a pres-
sure cuff placed around the proximal phalanx, and the
time taken to reach RBCVmax (TRBCVmax) were mea-
sured with a final magnification of x680, before and dur-
ing the post-occlusive reactive hyperemia response.
Conceptually, functional capillary density and RBCV
tested at rest, and RBCVmax and TRBCVmax assessed
during post-occlusive reactive hyperemia, are considered
functional variables. Time resolution for velocity mea-
surements for the non-interlaced 30 video frames per
second (fps) used, corrected for image persistence, is 0.2
s. Nailfold videocapillaroscopy is a well-validated
method, and our intra-assay coefficients of variation
have been previously reported [7,25].
Statistical analysis
We used StatSoft, 2004 software (STATISTICA, version
7; Tulsa, OK, USA) for data analysis, and variables were
tested regarding their problems of distribution (i.e., nor-
mality, kurtosis, skewness, and homoscedasticity). BMI,
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ing plasma glucose, insulin, total cholesterol, HDL-c,
LDL-c, TG, and CRP, and functional capillary density,
RBCV, RBCVmax, and TRBCVmax were all Z-standardized
and subsequently analyzed. PCA is a classical multivariate
statistical technique that was first described by Pearson in
1901 [29], and after the advent of the electronic compu-
ters, it became one of the more usual multivariate data
mining approaches[30]. The main aim of this method is to
detect the common variation between original variables,
and then condense a large dataset into a few derived vari-
ables, named as principal components (PCs). The obtained
principal components are linear combinations of original
variables with some degree of correlation between them.
The different principal components, however, are – by
definition – uncorrelated among themselves. Therefore,
the first component obtained in this analysis accounts for
a maximal amount of total variation between variables,
while the following component will account for the max-
imal amount of variance not accounted for by the prece-
dent one. This means that the second component will be
more correlated with some of the observed variables that
did not display strong correlations with the first one, and
therefore, it will be uncorrelated with the first component.
These assumptions are the same for the remaining com-
ponents that are extracted in the analysis, meaning that
each new component will progressively account for
smaller and smaller amounts of variance, expressed by
“eigenvalues”. The eigenvalue is the sum of squared cor-
relations between original independent variables and the
principal components obtained, and it represents the
amount of variance attributable to each component. We
used the Kaiser-Guttman method for principal compo-
nents selection (i.e., eigenvector Lambda’s >1, and the
plot of eigenvalues according to components [scree-plot]
as indicative of the relevance of the principal compo-
nent for interpretation of the data) [31,32]. The degree
of correlation between variables and principal compo-
nents are given by variable loadings. Therefore, the
higher the loading value is, the higher the influence of
a given variable on a principal component. Based on
variables with higher loadings, the biological meaning of
the principal components can be interpreted. In our
study, the cutoff for variable loadings was arbitrarily
established as ≥0.45, and those with higher values were
considered as main contributor(s) to each principal
component and used to define meanings (principal
component labels) [33].
Since the principal components are derived variables,
each individual included in the experiment has a score
related to each principal component. Based on these
scores, each subject was grouped a posteriori according
to BMI classes and metabolic syndrome diagnosis, and
then differences between these groups were tested byanalysis of variance (ANOVA). P values ≤0.05 were con-
sidered statistically significant.
Results
Table 1 depicts anthropometrical, clinical-laboratorial,
and functional microvascular variables of 189 female
subjects. Thirty-five percent (n=66) of the subjects had
metabolic syndrome and 77% (n=146) were overweight.
None of the subjects were at the pre-pubertal stage, 67%
(n=127) were of fertile age, and 33% (n=62) were in the
postmenopausal period. Metabolic syndrome was diag-
nosed according to age as follows: 36% (n=13) of sub-
jects were ≤18 years (19% [n=36]); 32% (n=22) of
subjects were between 19–30 years (36% [n=68]); 50%
(n=20) of subjects were between 31–50 years (21%
[n=40]); and 24% (n=11) of subjects were ≥51 years (24%
[n=45]). Fifty-nine subjects (31.2%) were normotensive,
89 (47.1%) had prehypertension, 35 (18.5%) were at stage
1 hypertension, and 6 (3.2%) were at stage 2 but without
ongoing treatment. All subjects with ≥JNC 7 stage 1
were referred to the outpatient care unit for treatment.
Eighteen (9.5%) subjects had impaired fasting glucose,
but all of them had a 2-h post-load glucose below 7.8
mmol/l.
According to the Kaiser-Guttman method [31], only the
first five principal components had eigenvalues ≥ 1.0 and
accounted for 72.5% of the total variation. Loadings of
more related variables to each principal component are
presented in Table 2. For principal component 1, which
explained 29% of the variation, 11 variables presented
loads higher than the established cutoffs, showing a strong
relationship among BMI, waist circumference, systolic and
diastolic BP, insulin levels, TG levels, CRP levels, and
TRBCVmax in the same way of variation, and also a strong
association among HDL-c, RBCV, RBCVmax, but in the
opposite way. For principal component 2, two variables
(total cholesterol and LDL-c levels) reached the cutoff
value, accounting for 16.5% of the variation. Explaining
12% of the total variation, only microvascular variables
(functional capillary density, RBCV and RBCVmax) loaded
principal component 3. Unexpectedly, fasting plasma glu-
cose appeared for the first time only in principal compo-
nent 4, contributing to 8% of the variation, but without an
association with any microvascular variable. For principal
component 5, which explained 7% of the variation, only
diastolic BP presented with a load higher than the estab-
lished cutoff. One of the assumptions of this statistical
method allows the designation of principal components
according to what they appear to express from a biological
view. Principal component 1 could be designated as the
abdominal obesity and insulin resistance component, clin-
ically expressed as metabolic syndrome, with principal
component 2 as the dyslipidemic component. Principal
component 3 could be designated as the microvascular
Table 1 Anthropometrical, clinical-laboratorial, and




Age (years) 29 [20.5-49.5] (12–64)
BMI (kg/m2) 30.5±7.1 (16.2-56.4)
Waist circumference (cm) 92.6±15.72 (60–146)
Systolic blood pressure (mmHg) 125.1±16 (80–182)
Diastolic blood pressure(mmHg) 74.8±10 (50–123)
Fasting plasma glucose (mmol/l) 4.86±0.55 (3.27-6.94)
Insulin (pmol/l) 76.06 [45.6-123.7] (13.1-333.3)
Total cholesterol (mmol/l) 4.86±1.09 (1.68-8.10)
Triglycerides (mmol/l) 1.33±0.66 (0.30-3.83)
HDL cholesterol (mmol/l) 1.33±0.39 (0.46-2.53)
LDL cholesterol (mmol/l) 2.92±0.93 (0.73-5.82)
C-reactive protein (mg/l) 3.00 [1.15-6.85] (0.3-20)
FCD (cap/mm2) 10.0 [7.6-14.4] (4.3-29.16)
RBCV (mm/s) 0.30±0.08 (0.07-0.41)
RBCVmax (mm/s) 0.36±0.05 (0.12-0.48)
TRBCVmax (s) 8.37±2.29 (3–15)
FCD, functional capillary density; RBCV, baseline red blood cell velocity;
RBCVmax, peak red blood cell velocity; TRBCVmax, time taken to reach RBCVmax
during the reactive hyperemia response.
Table 2 Variable loadingsa related to each principal
component
Principal Components
PC1 PC2 PC3 PC4 PC5
BMI 0,80 0,20 −0,23 0,20 −0,28
Waist circumference 0,75 0,23 −0,39 0,18 −0,15
Systolic blood pressure 0,72 −0,21 0,03 0,39 0,38
Diastolic blood pressure 0,56 −0,38 0,03 0,35 0,54
Fasting plasma glucose 0,19 −0,15 −0,31 −0,59 0,36
Insulin 0,62 0,35 −0,32 −0,17 −0,11
Total cholesterol −0,03 −0,95 0,00 −0,04 −0,23
Triglycerides 0,45 −0,42 −0,20 −0,44 −0,07
HDL cholesterol −0,55 −0,24 0,41 0,20 −0,09
LDL cholesterol 0,05 −0,88 −0,12 0,02 −0,22
C-reactive protein 0,50 −0,05 0,23 0,30 −0,37
FCD −0,29 −0,13 −0,63 0,14 −0,22
RBCV −0,58 0,01 −0,65 0,24 0,10
RBCVmax −0,67 −0,15 −0,51 0,27 0,14
TRBCVmax 0,52 −0,36 0,01 −0,06 0,05
Proportion of total variation 29% 16.5% 12% 8% 7%
aLoading denotes the contribution of the variable to each PC. Higher absolute
value indicates that the variable has a major influence on the PCs. Bolded
numbers indicate loadings ≥ 0.45.
PC, principal component; FCD, functional capillary density; RBCV, baseline red
blood cell velocity; RBCVmax, peak red blood cell velocity; TRBCVmax, time taken
to reach RBCVmax during the reactive hyperemia response.
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viewed as glycemic and pressure components, respect-
ively. All of the analyses described above were performed
excluding subjects ≤18 years. RBCVmax loading on princi-
pal component 3 lost its significance, but any other signifi-
cant difference was not observed (data not shown).
Using BMI as a grouping variable, we categorized our
subjects as normal weight, overweight, and obese, and
observed significant differences in four principal compo-
nents (PC1: p<0.001; PC2: p<0.01; PC3: p<0.01; PC5:
p<0.01). According to their principal component 1
scores, chosen BMI classes could be differentiated
(Tukey’s HSD, p<0.001), where normal weight subjects
were more related to HDL-c, RBCV, and RBCVmax,
while obese subjects were more related to higher values
of variables that were composed of principal compo-
nent 1 (BMI, waist circumference, systolic BP, diastolic
BP, insulin levels, TG levels, CRP levels, and
TRBCVmax). Analysis of principal component 3 scores
according to BMI classes indicated significant differ-
ences between normal weight and overweight (Tukey’s
HSD, p<0.03), and also between normal weight and
obesity (Tukey’s HSD, p<0.01), with no difference be-
tween subjects who were overweight and those who
were obese. Normal weight subjects showed an associ-
ation with higher values of functional capillary density,
RBCV and RBCVmax.
Principal component 1 was the only component able
to show differences between subjects with and those
without metabolic syndrome (PC1: p<0.001), and this
diagnosis was associated with higher values of variables
intrinsically related to insulin resistance but also to a
prolonged microvascular reactive hyperemia response,
such as BMI, waist circumference, systolic BP, diastolic
BP, insulin, TG, CRP and TRBCVmax).
Discussion
Microvascular damage is a well-known complication of
type 2 diabetes, but data on microvascular damage in
non-diabetic obese subjects are still scarce. However,
there are some studies that have described a possible
etiopathogenetic relationship between states of meta-
bolic disorders without diabetes and microvascular de-
rangement [4,7]. We previously observed microvascular
dysfunction in normoglycemic metabolic syndrome sub-
jects [6], and also a possible effect of waist circumfer-
ence on microvascular reactive hyperemia responses [7].
In the current study, although some subjects were diag-
nosed with hypertension and impaired fasting glucose, at
microvascular assessment, none of them were using any
drug that could result in a drug bias for the analyzed
data. Consistent with our previously published data [34],
we observed that, although 9.5% of the subjects had
impaired fasting glucose, these levels of glycemia were
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ables in our exploratory analysis. These findings suggest
an etiopathogenetic relationship between microvascular
dysfunction and excessive adiposity, without establishing
a cause-effect relationship, but possibly antedating type
2 diabetes diagnosis. When comparing subjects by BMI
classes, our data supported that the level of adiposity
could be directly associated with microvascular dysfunc-
tion, in which a higher BMI was related to an impaired
microvascular reactivity, which is corroborated by pre-
vious findings even in the absence of conditions, such
as hypertension [35], hypercholesterolemia [36], and
hyperglycemia [37]. These findings suggest that obesity
and metabolic syndrome are related to microvascular
dysfunction.
Microvascular variables associated with clinical vari-
ables were present in two principal components, 1 and
3, with the latter expressing exclusively the microcircu-
lation. For principal component 1, which explained
most of the variance, RBCV and RBCVmax were both
associated with HDL-c levels on the same way, suggest-
ing that this lipoprotein could play a protective role in
the microcirculation. Additionally, obesity, mainly ab-
dominal adiposity, as expressed by BMI and waist cir-
cumference, were the main factors (higher factor
loadings) associated with the time taken to reach peak
red blood cell velocity (TRBCVmax) during the reactive
hyperemia response. Prolongation of the reactive hy-
peremia response was also associated with increased
blood pressure, insulinemia, and CRP levels in principal
component 1, reassuring our previous findings in other
small samples [4,6]. These data strongly suggest that
other mechanisms related to abdominal obesity rather
than hyperglycemia are involved in the observed pro-
longed time for the microvascular reactive hyperemia re-
sponse in early stages of metabolic diseases, and together
microcirculation and precocious metabolic derangement
as part of the same pathophysiological process without
establishing an exact cause-effect relationship.
In a nondiabetic lean/overweight population, Voidoni-
kola and co-workers [38] reported that long-term gly-
cemia levels are associated with endothelial dysfunction
only in lean individuals, while in overweight individuals,
this association is not apparent. Similarly, Han and co-
workers [39] reported that dysglycemia contributes to
impaired vascular function in non-obese subjects, but
in obese and diabetic subjects, obesity and insulin re-
sistance per se are more important determinants of
vascular function than dysglycemia. These recent stud-
ies examining macrovascular reactivity support and
parallel our findings on nutritive microcirculation be-
cause our population was predominantly composed of
obese female subjects with insulin resistance but with-
out hyperglycemia.Our study has some limitations. Sex specificities and
their effect on vascular homeostasis should be consid-
ered. The addition of male subjects might reinforce our
results, because the protective aspect of the female hor-
monal milieu is well-established in the cardiovascular lit-
erature, and our group was predominantly composed of
fertile female subjects. The large age range in the investi-
gated group led to differences in the prevalence of obes-
ity/metabolic syndrome and hormonal status, which
could also be viewed as a possible bias for the analysis,
but the proposed statistical procedure reduced this
age bias.
Conclusions
In conclusion, based on our PCA, we found that the nu-
tritive microcirculation of non-diabetic female subjects
with a wide age range and with different adiposity levels
and metabolic impairment, is associated with classic
clinical variables, but not with fasting plasma glucose
levels. Therefore, we postulate that, in our cross-
sectional study population, impaired fasting glucose is
not associated with precocious microvascular dysfunc-
tion, and obesity and metabolic syndrome per se appear
to be more important for observed relationships.
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